CSPC Innovation Pharmaceutical Co., Ltd.
SZSE:300765.SZ
23.56 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,472.95 | 2,626.489 | 1,431.988 | 1,317.414 | 1,256.502 | 1,240.099 | 1,031.181 | 890.477 | 742.01 | 650.716 |
| Cost of Revenue
| 1,389.947 | 1,491.57 | 746.117 | 584.198 | 611.842 | 631.371 | 527.204 | 470.053 | 458.225 | 397.86 |
| Gross Profit
| 1,083.002 | 1,134.918 | 685.871 | 733.216 | 644.661 | 608.728 | 503.977 | 420.424 | 283.786 | 252.856 |
| Gross Profit Ratio
| 0.438 | 0.432 | 0.479 | 0.557 | 0.513 | 0.491 | 0.489 | 0.472 | 0.382 | 0.389 |
| Reseach & Development Expenses
| 44.207 | 46.3 | 20.399 | 14.046 | 13.052 | 11.252 | 8.507 | 9.525 | 26.512 | 26.791 |
| General & Administrative Expenses
| 26.361 | 18.182 | 12.172 | 11.15 | 12.983 | 13.387 | 8.067 | 4.306 | 32.641 | 33.15 |
| Selling & Marketing Expenses
| 205.234 | 244.249 | 260.996 | 328.042 | 279.066 | 275.524 | 207.359 | 154.474 | 112.087 | 87.995 |
| SG&A
| 266.986 | 262.431 | 273.167 | 339.192 | 292.049 | 288.911 | 215.426 | 158.78 | 144.728 | 121.145 |
| Other Expenses
| 2.405 | -4.216 | -8.159 | 5.196 | 2.338 | 0.846 | -1.861 | 0.447 | 1.117 | 2.322 |
| Operating Expenses
| 308.789 | 375.232 | 322.278 | 390.483 | 340.254 | 333.352 | 255.498 | 201.068 | 152.106 | 126.576 |
| Operating Income
| 774.214 | 855.588 | 395.256 | 360.022 | 332.833 | 276.859 | 240.706 | 247.724 | 135.771 | 124.904 |
| Operating Income Ratio
| 0.313 | 0.326 | 0.276 | 0.273 | 0.265 | 0.223 | 0.233 | 0.278 | 0.183 | 0.192 |
| Total Other Income Expenses Net
| 104.993 | -4.216 | -8.159 | 5.196 | 2.338 | 0.846 | -1.861 | 0.447 | 1.117 | 2.176 |
| Income Before Tax
| 879.207 | 851.372 | 387.097 | 365.219 | 335.17 | 277.705 | 238.845 | 248.171 | 136.889 | 127.08 |
| Income Before Tax Ratio
| 0.356 | 0.324 | 0.27 | 0.277 | 0.267 | 0.224 | 0.232 | 0.279 | 0.184 | 0.195 |
| Income Tax Expense
| 136.47 | 124.761 | 70.554 | 65.506 | 61.643 | 53.383 | 43.933 | 41.815 | 21.404 | 18.844 |
| Net Income
| 755.557 | 726.278 | 393.228 | 299.836 | 273.197 | 223.84 | 194.911 | 206.577 | 115.59 | 108.235 |
| Net Income Ratio
| 0.306 | 0.277 | 0.275 | 0.228 | 0.217 | 0.181 | 0.189 | 0.232 | 0.156 | 0.166 |
| EPS
| 0.65 | 0.65 | 0.4 | 0.31 | 0.28 | 0.3 | 0.26 | 0.28 | 0.16 | 0.092 |
| EPS Diluted
| 0.65 | 0.65 | 0.4 | 0.31 | 0.28 | 0.3 | 0.26 | 0.28 | 0.16 | 0.092 |
| EBITDA
| 874.311 | 932.237 | 444.912 | 415.284 | 379.321 | 327.58 | 278.391 | 263.64 | 156.991 | 147.523 |
| EBITDA Ratio
| 0.354 | 0.355 | 0.311 | 0.315 | 0.302 | 0.264 | 0.27 | 0.296 | 0.212 | 0.227 |